RTA compliance certificate filed under SEBI Reg 74(5) for Sep 2026 quarter

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.5%Reaction day

₹36.16

prior close

₹37.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+3.8% vs market

Pharmaceuticals peers, median of 173sector+0.0%+4.5% vs sector

On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

-1.3

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.5+0.7+3.8+0.0+4.5

Next day

+4.4-1.0+5.4-1.2+5.6

-0.8-3.6+2.8-3.0+2.2

-5.6-4.5-1.0-3.8-1.8

-8.7-6.8-2.0-5.0-3.7

-11.0-6.4-4.6-3.9-7.0

-7.4-4.7-2.7-0.9-6.5

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

ANG Lifesciences filed a routine compliance certificate to BSE from its Registrar Bigshare Services, under SEBI Regulation 74(5) for the quarter ended September 30, 2026. The RTA confirmed that dematerialization requests received from depository participants were properly processed and reported to depositories, securities were listed, physical certificates cancelled and mutilated, and depository names updated in the register of members within 15 days. This is a standard procedural compliance filing with no business or financial news.

Likely market impact

Routine regulatory compliance filing with no material impact on shareholders or stock price.